Interferons: Effectiveness, Toxicities, and Costs
Authors: Ernest C. Borden
Journal: Annals of Internal Medicine (1996)

Editorials1 October 1996Interferons: Effectiveness, Toxicities, and CostsErnest C. Borden, MD and David Parkinson, MDErnest C. Borden, MDUniversity of Maryland Cancer Center, Baltimore, MD 21201National Cancer Institute, Bethesda, MD 20892Search for more papers by this author and David Parkinson, MDUniversity of Maryland Cancer Center, Baltimore, MD 21201National Cancer Institute, Bethesda, MD 20892Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-125-7-199610010-00012 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Phase I, II, and III trials that defined the therapeutic effectiveness of interferons for neoplastic, viral, and immunologic diseases have helped improve the quantity and quality of life for thousands of patients. Hematologic malignant conditions have been particularly responsive to interferon treatment, but solid tumors have also been treated successfully. Interferon treatment has also decreased the duration of the symptom phases in viral diseases of DNA and RNA virus origin and have decreased the number and duration of complications of these diseases. As the use of interferons has become more widespread and duration of treatment has increased, these agents themselves ...References1. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol. 1986; 4:234-43. Google Scholar2. Kalvakolanu DV, Borden EC. An overview of the interferon system: signal transduction and mechanisms of action. Cancer Invest. 1996; 14:25-53. Google Scholar3. Gisslinger H, Gilly B, Woloszczuk W, Mayr WR, Havelec L, Linkesch W, et al. Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-α. Clin Exp Immunol. 1992; 90:363-7. Google Scholar4. Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N. The risk factor for development of thyroid disease during interferon-α therapy for chronic hepatitis C. Am J Gastroenterol. 1994; 89:399-403. Google Scholar5. Plata-Salaman CR. Interferons and central regulation of feeding. Am J Physiol. 1992; 263(6 pt 2):R1222-7. Google Scholar6. Kuriyama K, Hori T, Mori T, Nakashima T. Actions of interferon-α and interleukin-1 β on the glucose-responsive neurons in the ventromedial hypothalamus. Brain Res Bull. 1990; 24:803-10. Google Scholar7. Pavol MA, Meyers CA, Rexer JL, Valentine AD, Mattis PJ, Talpaz M. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology. 1995; 45:947-50. Google Scholar8. Quesada JR, Hawkins M, Horning S, Alexanian R, Borden E, Merigan T, et al. A collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma. Am J Med. 1984; 77:427-32. Google Scholar9. Silver HK, Connors JM, Salinas FA. Prospectively randomized toxicity study of high-dose versus low-dose treatment strategies for lymphoblastoid interferon. Cancer Treat Rep. 1985; 69:743-50. Google Scholar10. Wong D, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of α-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993; 119:312-23. Google Scholar11. Ackermann M, Kirchner H, Atzpodien J. Low dose megestrol acetate can abrogate cachexia in advanced tumor patients receiving systemic interferon-α and/or interleukin-2 based antineoplastic therapy. Anticancer Drugs. 1993; 4:585-7. Google Scholar12. Mulligan K, Grunfeld C, Hellerstein MK, Neese RA, Schambelan M. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab. 1993; 77:956-62. Google Scholar13. Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, van der Meer JW, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med. 1989; 320:265-71. Google Scholar14. Valentine AD, Meyers CA, Talpaz M. Treatment of neurotoxic side effects of interferon-α with naltrexone. Cancer Invest. 1995; 13:561-6. Google Scholar15. Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv Exp Med Biol. 1991; 294:425-35. Google Scholar16. Kattan MW, Inoue Y, Giles FJ, Talpaz M, Ozer H, Guilhot F, et al. Cost-effectiveness of interferon-α and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med. 1996; 125:541-8. Google Scholar17. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-α 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med. 1995; 122:664-75. Google Scholar18. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996; 14:7-17. Google Scholar19. Cole B, Gelber R, Kirkwood J, Goldhirsch A, Barylak E, Borden E. A quality of life adjusted survival analysis of interferon α 2B adjuvant treatment for high risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group Study (E1684). J Clin Oncol. 1996; [in press]. Google Scholar Author, Article, and Disclosure InformationAffiliations: University of Maryland Cancer Center, Baltimore, MD 21201National Cancer Institute, Bethesda, MD 20892Corresponding Author: Ernest C. Borden, MD, University of Maryland Cancer Center, 22 South Greene Street, Baltimore, MD 21201.Current Author Addresses: Dr. Borden: University of Maryland Cancer Center, 22 South Greene Street, Baltimore, MD 21201. Dr. Parkinson: Division of Cancer Treatment, National Cancer Institute, 16130 Executive Boulevard, Bethesda, MD 20892. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByTherapeutic Alpha-Interferons Protein: Structure, Production, and BiosimilarInvestigating Quality‐of‐Life in Clinical TrialsMaintenance therapy in cutaneous T-cell lymphoma: Who, when, what?The optimal use of bexarotene in cutaneous T-cell lymphomaFatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal studyCytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2Interferon in the treatment of cutaneous T-cell lymphomaThe Role of IFN-γ in Surgical PatientsPathophysiologic and Clinical Role of Interferon-γ and its Release Triggering Cytokines IL-12 and IL-18Role of Interferon-α in the treatment of primary glomerulonephritisEffects of IFN-β on Human Cerebral Blood Flow DistributionNew Advances in Interferon Therapy of Cancer 1 October 1996Volume 125, Issue 7Page: 614-615KeywordsChronic myelogenous leukemiaCytokinesFatigueHepatitis BInterferonsQuality of lifeThyroidToxicityViral diseasesWeight loss Issue Published: 1 October 1996 CopyrightCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...